UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 193,588 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 10.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,116,573 shares of the company's stock after acquiring an additional 193,588 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 1.75% of 10x Genomics worth $30,394,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC grew its stake in 10x Genomics by 0.6% during the fourth quarter. FMR LLC now owns 13,454,434 shares of the company's stock worth $193,206,000 after buying an additional 86,455 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of 10x Genomics by 11.1% in the 4th quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock worth $171,517,000 after acquiring an additional 1,193,712 shares in the last quarter. RA Capital Management L.P. bought a new stake in 10x Genomics during the 4th quarter worth approximately $47,092,000. Voloridge Investment Management LLC increased its holdings in 10x Genomics by 12.1% during the 4th quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock valued at $22,774,000 after purchasing an additional 171,161 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in 10x Genomics by 291.2% in the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after purchasing an additional 982,203 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,485 shares of the company's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total value of $62,125.50. Following the transaction, the insider now directly owns 448,374 shares of the company's stock, valued at $3,721,504.20. This represents a 1.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Adam Taich sold 4,044 shares of the business's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the completion of the sale, the chief financial officer now directly owns 331,588 shares of the company's stock, valued at approximately $2,752,180.40. The trade was a 1.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,872 shares of company stock worth $173,238 over the last quarter. 9.39% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on TXG. The Goldman Sachs Group dropped their target price on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research note on Monday, May 12th. Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Morgan Stanley cut their price objective on shares of 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday, May 24th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, 10x Genomics presently has an average rating of "Hold" and a consensus target price of $15.81.

10x Genomics Stock Up 2.0%

Shares of NASDAQ:TXG traded up $0.19 during mid-day trading on Friday, reaching $9.53. 4,649,044 shares of the stock were exchanged, compared to its average volume of 2,417,694. The company has a market cap of $1.17 billion, a P/E ratio of -6.27 and a beta of 1.94. The stock's 50 day simple moving average is $8.47 and its 200-day simple moving average is $11.88. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. The business had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. 10x Genomics's quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.50) earnings per share. Analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.